World of DTC Marketing

JUNE 1, 2021

At one point, Biogen was down as an innovative biotech company in Weston, Massachusetts. If the drug is approved you can bet that it’s going to carry a huge price tag. It could carry a price tag as high as $50,000-a-year per patient, according to drug analysts, adding billions of dollars to the nation’s health tab. .

Side effects 187

Side effects FDA Patients Doctors 187

World of DTC Marketing

SEPTEMBER 24, 2021

I remember when Biogen was an exciting new biotech based in Westin. Then, against the advisory panel’s advice, Aduhelm was approved, but insiders within the industry criticized both the FDA and Biogen weren’t sold on the drug or its price tag. He has zero credibility with the HCP community.

Insurance 222

Insurance Pharma Doctors Physicians 222

World of DTC Marketing

SEPTEMBER 7, 2022

In pharma, growth depends on new products with hefty price tags when over 80% of voters want lower costs for their prescription drugs. Rather than investing more in R&D, most pharma companies feel its more cost-effective to buy small biotech companies developing unique molecules that can find a market niche.

Pharma 210

Pharma Food and Drug Administration Marketing Prescription 210

pharmaphorum

AUGUST 25, 2022

It joins a number of other BCMA-directed therapies for multiple myeloma, including GSK’s first-to-market antibody-drug conjugate Blenrep (belantamab mafodotin), Bristol-Myers Squibb/bluebird bio’s CAR-T therapy Abecma (idecabtagene vicleucel) and J&J/Legend Biotech’s CAR-T Carvykti (ciltacabtagene autoleucel).

FDA 94

FDA Marketing Safety Patients 94

pharmaphorum

AUGUST 21, 2022

The biotech hasn’t revealed much information about the reasons for the delay in getting approval, but said in an SEC filing in June this year that it had agreed to “post-marketing commitments” proposed by the FDA, without going into details.

FDA 89

FDA Marketing Pharma Sales 89

pharmaphorum

DECEMBER 12, 2022

Dutch biotech Argenx is on course to add another rare disease indication to the label of its FcRn blocker Vyvgart – primary immune thrombocytopenia (ITP) – thanks to new data reported at the ASH annual meeting.

Side effects 52

Side effects Sales Competition Patients 52

pharmaphorum

DECEMBER 23, 2022

price tag of $475,000 when it was first launched in 2017 – and it becomes apparent that these may not be desirable treatment options for every patient and in every setting. Add to this the considerable cost of these medications – the first approved CAR-T, Novartis’ Kymriah (tisagenlecleucel), had a U.S. Oral therapy data presented at ASH.

Side effects 52

Side effects Patients Medical Medicine 52